| Name | Title | Contact Details |
|---|
Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so difficult. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At Agios, we`re always looking for the sweet spot between exhilaration and anxiety – while being respectful, kind and connected with each other so we can flourish. At our core, we`re a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients. We`re a science-driven, global organization that`s built a discovery platform on our expertise across three major focus areas: cancer metabolism, rare genetic diseases and metabolic immuno-oncology. And we care. A lot. Patients are counting on us, and we`re driven by a sense of urgency to help. We challenge ourselves to think big and welcome different perspectives and backgrounds. And we deliver. We have two approved oncology precision medicines and multiple first-in-class investigational therapies in development. So far. Through it all, we are propelled by our connections. We believe in our people to be…just who they are. We believe in our work and in each other – in enjoying this journey together so that we can achieve the Other Side of Possible.
CANTEST Ltd is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elevation Spine is a medical device company with a proprietary technology platform, Saber Technology, which is an advanced and differentiated approach to spinal fusion. The fusion procedure is highly efficient while remaining minimally invasive.
SubjectWell provides risk-free patient recruitment for clinical trials. We engage the 96% of Americans who have never participated in clinical trials and we only charge for those who randomize.
Montana Health Research Inst is a Billings, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.